Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sihuan Pharmaceutical Holdings Group Ltd. has announced that its subsidiary, Honghe Pharmaceutical, received approval from China’s National Medical Products Administration for their Ticagrelor Orodispersible Tablet, a novel antithrombotic medication. This first domestic product approval marks a significant addition to the Group’s cardiovascular drug portfolio and is expected to positively impact its operating performance in a market exceeding RMB 10 billion in 2023.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.